Universe Pharmaceuticals Stock (NASDAQ:UPC)

Revenue Ownership Financials Chart

Previous Close

$1.67

52W Range

$0.38 - $4.32

50D Avg

$3.44

200D Avg

$2.35

Market Cap

$12.86M

Avg Vol (3M)

$1.47M

Beta

1.67

Div Yield

-

UPC Company Profile

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CN

Employees

225

IPO Date

Mar 23, 2021

Website

UPC Performance

UPC Financial Summary

	Sep 23	Sep 22	Sep 21
Revenue	$32.31M	$40.14M	$47.98M
Operating Income	$-3.53M	$-7.02M	$13.59M
Net Income	$-6.16M	$-8.74M	$11.32M
EBITDA	$-3.66M	$-6.40M	$13.99M
Basic EPS	-	$-0.42	$0.60
Diluted EPS	-	$-0.42	$0.60

Fiscal year ends in Sep 23 | Currency in USD

Peer Comparison

Ticker	Company
QLI	Qilian International Holding Group Limited
TKNO	Alpha Teknova, Inc.
PAHC	Phibro Animal Health Corporation
RGC	Regencell Bioscience Holdings Limited
SSIC	Silver Spike Investment Corp.
PROC	Procaps Group S.A.
IMCC	IM Cannabis Corp.
EGRX	Eagle Pharmaceuticals, Inc.